Author Topic: Pfizer Asks Court to Dismiss Whistleblower Lawsuit Because Govt Aware of Fraud  (Read 964 times)

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090
https://childrenshealthdefense.org/defender/pfizer-whistleblower-lawsuit-fraud/

"Pfizer Asks Court to Dismiss Whistleblower Lawsuit Because Government Was Aware of Fraud
07/05/22

In an interview with The Defender, the lawyer representing whistleblower Brook Jackson said Pfizer is arguing the court should dismiss Jackson’s lawsuit alleging fraud in Pfizer’s COVID-19 clinical trials because the U.S. government knew about the wrongdoings but continued to do business with the vaccine maker.
By
Michael Nevradakis, Ph.D.

A lawsuit filed by whistleblower Brook Jackson alleging Pfizer and two of its contractors manipulated data and committed other acts of fraud during Pfizer’s COVID-19 clinical trials is paused following a motion by the defendants to dismiss the case.

In an interview with The Defender, Jackson’s lawyer said Pfizer argued the lawsuit, which was filed under the False Claims Act, should be dismissed because the U.S. government knew of the wrongdoings in the clinical trials but continued to do business with the vaccine maker.

Under the False Claims Act, whistleblowers can be rewarded for confidentially disclosing fraud that results in a financial loss to the federal government.

However, a 2016 U.S. Supreme Court decision that expanded the scope of a legal principle known as “materiality” resulted in a series of federal court decisions in which fraud cases brought under the False Claims Act were dismissed.

As interpreted by the Supreme Court, if the government continued paying a contractor despite the contractor’s fraudulent activity, the fraud was not considered “material” to the contract.

Pfizer is a federal contractor because it signed multiple contracts with the U.S. government to provide COVID-19 vaccines and Paxlovid, a pill used to treat the virus.

“Pfizer claims they can get away with fraud as long as the government would write them a check despite knowing about the fraud,” attorney Robert Barnes said.

The other two defendants in the case are Ventavia Research Group, which conducted vaccine trials on behalf of Pfizer, and ICON PLC, also a Pfizer contractor.

In an attempt to strengthen the False Claims Act’s anti-retaliation provisions and install new safeguards against industry-level blacklisting of whistleblowers seeking employment, Congress in July 2021 introduced the False Claims Amendments Act of 2021.

In December 2021, Pfizer hired a well-connected lobbyist, Hazen Marshall, and the law firm Williams & Jensen to lobby against the bill.

Pfizer previously was heavily fined in connection with the False Claims Act. As part of a 2009 settlement, the company paid $2.3 billion in fines — the largest healthcare fraud settlement in the history of the U.S. Department of Justice — stemming from allegations of illegal marketing of off-label products not approved by the U.S. Food and Drug Administration (FDA).

“Pfizer, one of the most criminally fined drug companies in the world, wants to weaken the laws that hold them accountable,” Barnes told The Defender.

Congress has taken no action on the False Claims Amendments Act since November 2021, when the bill was added to the Senate’s legislative calendar.

Barnes said the outcome of Jackson’s case against Pfizer is significant not just for his client, but also for the American public.

“This case will determine if Big Pharma can rip off the American people using a dangerous drug that harms millions without any legal remedy because they claim the government was in on the scam.”

Jackson was a regional director for Ventavia for a brief period in 2020 but was fired after she notified the FDA about issues with Pfizer’s vaccine trials.

After she was fired, she gave The BMJ a cache of internal company documents, photos and recordings highlighting the alleged wrongdoing by Ventavia.

The documents she provided contained evidence of falsified data, blind trial failures and awareness on the part of at least one Ventavia executive that members of the company’s staff were “falsifying data.”

Jackson’s documents also provided evidence of administrators who had “no training” or medical certifications, or who provided “very little oversight” during the trials.

Jackson filed her complaint in August 2021, in the U.S. District Court, Eastern District of Texas, Beaumont Division, alleging Pfizer, Ventavia and ICON “deliberately withheld crucial information from the United States that calls the safety and efficacy of their vaccine into question.”

A district court judge in February unsealed Jackson’s complaint, which included 400 pages of exhibits.

According to the complaint, Jackson, who had more than 15 years of experience working with clinical trials, “repeatedly informed her superiors of poor laboratory management, patient safety concerns and data integrity issues” during the approximately two weeks she was employed by Ventavia.

“Brook [Jackson] brought a Qui Tam action and a retaliatory discharge case against Pfizer and others for fraud on the people concerning Pfizer’s false certifications to the U.S. Department of Defense about the safety and efficacy of their COVID-19 vaccine,” Barnes said.

A Qui Tam case refers to a provision under the False Claims Act that allows individuals and entities with evidence of fraud against federal programs or contracts to sue the wrongdoer on behalf of the U.S. government

“She was part of the clinical trials, witnessed extraordinary malfeasance, blew the whistle, and was quickly fired after she blew the whistle.”

Barnes said his legal team will in August file its opposition brief to Pfizer’s motion to dismiss, and the judge may rule on the motion to dismiss by fall 2022."
______________________________________


Judge Unseals 400 Pages of Evidence, Clears Way for Pfizer Whistleblower Lawsuit
03/01/22
https://childrenshealthdefense.org/defender/judge-evidence-pfizer-whistleblower-lawsuit/
« Last Edit: August 29, 2022, 11:31:34 AM by admin »
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090

https://www.bitchute.com/video/HunfOivPBOTY/

Brook Jackson Interview - Pfizer Whistleblower Exposes Cover Up Calling Vaccine Data Into Question
The Last American Vagabond
https://www.bitchute.com/search/?query=brook%20jackson&kind=video

Brook Jackson Interview - Pfizer Whistleblower Exposes Cover Up Calling Vaccine Data Into Question
https://www.bitchute.com/video/4ZAuiwJboP3s/
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090
https://www.icandecide.org/ican_press/ican-demands-answers-about-death-discrepancies-in-pfizers-clinical-trial/

"For the second time, the FDA has avoided answering very simple questions about discrepancies concerning the numbers of deaths in Pfizer’s clinical trial, citing “resource constraints” and blaming its workload, in part, on ICAN’s FOIA requests.

Back in February, ICAN announced it sent a letter to the FDA regarding discrepancies in the reports of death in the Pfizer Covid-19 clinical trial data. Specifically, ICAN sought answers to two questions, both critically important because in Pfizer’s Covid-19 vaccine clinical trial the final death count in the vaccine group was higher than in the placebo group:

    Why do the death counts in the Statistical Review not add up to the numbers in the Clinical Review Memo from which they are said to be sourced and why do both of those differ from the death counts in the Summary Basis for Regulatory Action?
    Why are the death data from a randomized controlled trial (“RCT”) treated like a clinical case-series rather than an RCT when it comes to assessing causality? And can you confirm that causality (a biostatistical construct in this case) is being assessed by biostatisticians rather than by clinicians?

Despite the enormity of the issue that ICAN was raising – people who died during a clinical trial – the FDA failed to respond, prompting ICAN to send a follow up on April 2022 reiterating those same two questions.

Incredibly, when the FDA did respond, it did not provide an answer to either of the two questions posed.  Instead, the individuals at FDA’s Center for Biologics Evaluation and Research took the time to contact the FDA’s FOIA office and obtain a count of the total number of ICAN’s outstanding FOIA requests and then cite them as the reason it was unable to “respond substantively”:

    "We are unable to respond substantively at this time due to resource constraints and the ongoing pandemic response.  It is thus necessary for the Agency to prioritize its responses to individual inquiries.  We note that the Agency is providing to your law firm, in response to a FOIA request, an unprecedented volume of records that comprise the license application for this product.  Additionally, there are more than 50 pending FOIA requests submitted by your firm for data and information about COVID‐19 vaccines."

Perhaps the FDA should have properly done its job when approving Pfizer’s vaccine.  Then it would not need to devote an incredible amount of resources to trying to cover-up its abject failure in approving and promoting a product with serious safety and efficacy issues.  That would free up a lot of FDA time – just being transparent and honest about its mistakes.  Consider this: in the time it took to obtain the FOIA count, the FDA could have simply provided a substantive and adequate response to the questions asked.  These are dead people – one would imagine you would have the numbers right.  The FDA instead chooses to avoid answering by giving an excuse akin to “my dog ate my homework.”

This is yet another exhibit in the mountain of evidence as to why the FDA needs to be dismantled and rebuilt form the ground-up as an organization that actually serves the public interest and not that of pharma and its political handlers.  ICAN intends to continue to shine a light on these issues until this comes to pass."
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090
At least vaxx makers detailed the ingredients and adverse events in their package inserts, as required and demonstrated by the video below:

" 1. Information Relating to the EUA Product
a. Information for Health Care Professionals or Authorized Dispensers

For an unapproved product (section 564(e)(1)(A)(i)) and for an unapproved use of an approved product (section 564(e)(2)(A)), FDA must (to the extent practicable given the circumstances of the emergency) establish conditions to ensure that health care professionals who administer the EUA product are informed:

    That FDA has authorized the emergency use of the product (including the product name and an explanation of its intended use);
    Of the significant known and potential benefits and risks of the emergency use of the product, and the extent to which such benefits and risks are unknown; and
    Of available alternatives and their benefits and risks.

Therefore, FDA recommends that a request for an EUA include a “Fact Sheet" for health care professionals or authorized dispensers that includes essential information about the product.  In addition to the required information, Fact Sheets should include:

    A description of the disease/condition;
    Any contraindications or warnings;
    Dosing information (if applicable), including any specific instructions for special populations; and
    Contact information for reporting adverse events and additional information about the product.

Health care professionals or authorized dispensers will likely have very limited time to review Fact Sheets during an emergency and, therefore, FDA anticipates that Fact Sheets typically will be brief (i.e., a few pages).  FDA makes available on its website Fact Sheets for products for which an EUA is issued.41"
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities#processing


« Last Edit: August 30, 2022, 11:36:19 AM by admin »
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090
« Last Edit: December 04, 2022, 03:41:34 PM by admin »
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment